To the Editor Drs Gottlieb and Punjabi, in their Review on obstructive sleep apnea (OSA),1 stated that “current evidence suggests that treatment does not reduce the risk of cardiovascular disease, stroke, or metabolic abnormalities in asymptomatic patients.” Even though studies have failed to find a decrease in cardiovascular mortality in patients using continuous positive airway pressure (PAP), they have had significant methodological flaws, such as excluding patients with excessive sleepiness—precisely the patients who need continuous PAP therapy.2
Hunasikatti M. Benefits of Treating Obstructive Sleep Apnea. JAMA. 2020;324(11):1110. doi:10.1001/jama.2020.11848
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: